Spots Global Cancer Trial Database for Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma

Official Title: Evaluation of a Web Application on Event Reporting for Patients With B Lymphoma on First Line Treatment

Study ID: NCT05298293

Conditions

Diffuse Large B Cell Lymphoma

Interventions

ONCOLAXY Follow-up

Study Description

Brief Summary: Diffuse large B cell lymphoma is the most common malignant lymphoid hemopathy. More than half of the patients will be cured with an RCHOP-type immunochemotherapy protocol (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone). Monitoring of adverse effects, risk of relapse and quality of life are essential in overall management. Patients are the best candidates to report them. Managing these events should improve quality of life and reduce costs. The aim of this study is to assess the feasibility of monitoring these events by a web application (Oncolaxy©) and to compare it with a control population in the context of a randomized pilot study including 80 patients per arm with diffuse large cell B lymphoma in first-line treatment with R-CHOP.

Detailed Description: